非小细胞肺癌|【权威发布】非小细胞肺癌PD-L1免疫组织化学检测规范中国专家共识( 六 )


20 NCCN Clinical Practice Guidelines for non-small cell lung cancer (version 3.2020). Available at: https://www.nccn.org/
21 Mok TSK, Wu YL, Kudaba I, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet, 2019, 393(10183): 1819-1830. doi: 10.1016/S0140-6736(18)32409-7
22Harrington KJ, Ferris RL, Blumenschein G Jr, et al. Nivolumab versus standard, single-agent therapy of investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): hea lth-related qua lit y-of-life results f rom a randomised, phase 3 trial. Lancet Oncol, 2017, 18(8): 1104-1115. doi: 10.1016/ S1470-2045(17)30421-7
23Heymann JJ, Bulman WA, Swinarski D, et al. PD‐L1 expression in non‐small cell lung carcinoma: comparison among cytology, small biopsy, and surgical resection specimens. Cancer Cytopathol, 2017, 125(12): 896-907. doi: 10.1002/cncy.21937
24Skov BG, Skov T. Paired comparison of PD-L1 expression on cytologic and histologic specimens from malignancies in the lung assessed with PD-L1 IHC 28-8pharmDx and PD-L1 IHC 22C3pharmDx. Appl Immunohistochem Mol Morphol, 2017, 25(7): 453-459. doi: 10.1097/ PAI.0000000000000540
25Lozano MD, Abengozar‐Muela M, Echeveste JI, et al. Programmed death-ligand 1 expression on direct Pap‐stained cytology smears from non-small cell lung cancer: Comparison with cell blocks and surgical resection specimens. Cancer Cytopathol, 2019, 127(7): 470-480. doi: 10.1002/cncy.22155
26Kuempers C, van der Linde LIS, Reischl M, et al. Comparison of PD-L1 expression between paired cytologic and histologic specimens from non-small cell lung cancer patients. Virchows Arch, 2020, 476(2): 261-271. doi: 10.1007/s00428-019-02632-7
27Ca p i z z i E , R i c c i C, Gi u n c h i F, e t a l . Va l i d a t i o n o f t h e immunohistochemical expression of programmed death ligand 1 (PD-L1) on cytological smears in advanced non small cell lung cancer. Lung Cancer, 2018, 126: 9-14. doi: 10.1016/j.lungcan.2018.10.017
28Li Y, Chen J. Current challenges with PD-L1 testing for immunotherapy biomarkers in non-small cell lung cancer. Zhonghua Bing Li Xue Za Zhi, 2019, 48(8): 585-589. [李媛, 陈杰. PD-L1检测在非小细胞肺癌免疫治疗标志物筛选中面临的挑战. 中华病理学杂志, 2019, 48(8): 585-589.] doi: 10.3760/cma.j.issn.0529?5807.2019.08.001
29Midha A, Sharpe A, Scott M, et al. PD-L1 expression in advanced NSCLC: Primary lesions versus metastatic sites and impact of sample age. J Clin Oncol, 2016, 34(15 suppl): 3025. doi: 10.1200/JCO.2016.34 .15_suppl.3025
30Ts ao MS , Ke r r KM, Da c i c S , e t a l . I ASLC At l a s of PD-L1 Immunohistochemistr y testing in lung cancer. 1st ed. Aurora: International Association for the Study of Lung Cancer, 2017.
31Hewitt SM, Robinowitz M, Bogen SA, et al. Quality assurance for design control and implementation of immunohistochemistry assays: Approved guideline. 2nd ed. Wayne: Clinical and Laboratory Standards Institute, 2011. 75-76.
32Guo XJ, Cao H, Zhou JY, et al. Progress on the Study of PD-L1 Detection Methods in Non-small Cell Lung Cancer. Zhongguo Fei Ai Za Zhi, 2019, 22(1): 46-50. [郭雪晶, 曹赫, 周建娅, 等. PD-L1检测方法在非小细胞肺癌的研究进展. 中国肺癌杂志, 2019, 22(1): 46-50.] doi: 10.3779/j.issn.1009-3419.2019.01.08
33Lin DM. Current Status of PD-L1 Testing in Non-small cell lung cancer in China. Zhonghua Bing Li Xue Za Zhi, 2017, 46(10): 665-668. [林 冬梅. 中国非小细胞肺癌PD-L1检测现状. 中华病理学杂志, 2017, 46(10): 665-668.] doi: 10.3760/cma.j.issn.0529-5807.2017.10.001
34 Jiang LL, Li Y, Ying JM. Detection of PD-L1 Expression in Non-Small Cell Lung Cancer: Current Status. Zhonghua Bing Li Xue Za Zhi, 2018, 47(11): 887-890. [蒋莉莉, 李媛, 应建明. 非小细胞肺癌PD-L1表 达检测及应用现状. 中华病理学杂志, 2018, 47(11): 887-890.] doi: 10.3760/cma.j.issn.0529-5807.2018.11.021

推荐阅读